[go: up one dir, main page]

EP3380065B1 - Personal care compositions - Google Patents

Personal care compositions Download PDF

Info

Publication number
EP3380065B1
EP3380065B1 EP16826653.4A EP16826653A EP3380065B1 EP 3380065 B1 EP3380065 B1 EP 3380065B1 EP 16826653 A EP16826653 A EP 16826653A EP 3380065 B1 EP3380065 B1 EP 3380065B1
Authority
EP
European Patent Office
Prior art keywords
weight
composition
tin
ppm
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16826653.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3380065A1 (en
Inventor
Shiri NAWROCKI
Viktor DUBOVOY
Long Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of EP3380065A1 publication Critical patent/EP3380065A1/en
Application granted granted Critical
Publication of EP3380065B1 publication Critical patent/EP3380065B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A61K8/21—Fluorides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging
    • A61K2800/874—Roll-on

Definitions

  • antiperspirants designed to help people reduce sweat. Examples of these can be found in U.S. Code of Regulation 21 C.F.R. ⁇ 350.
  • the majority of the active agents used in antiperspirants are aluminum and zirconium halide compounds and complexes and their derivatives. While these active agents are generally effective, there is still a need for alternative antiperspirant actives.
  • Tin (II) fluoride also known as stannous fluoride, SnF 2
  • Tin (II) fluoride is soluble in water, however, it oxidizes to form insoluble precipitates of tin.
  • tin can form insoluble compounds with phosphates.
  • tin (II) compounds for instance tin (II) fluoride and tin (II) chloride, to make them effective in personal care products.
  • Embodiments of the present invention are designed to meet these, and other, needs.
  • tin (II) fluoride and tin (II) chloride form aqueous soluble tin phosphate complexes upon mixture with a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ) (STPP).
  • a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ) (STPP).
  • the aqueous soluble tin phosphate complexes form a white precipitate, which may be an appropriate occlusive active for wetness control because it forms plugs that can physically inhibit sweat from skin.
  • aqueous soluble tin phosphate complexes e.g., formed from a mixture comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 R 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ), e.g., sodium tripolyphosphate (Na 5 P 3 O 10 )
  • a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 R 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ), e.g., sodium tripolyphosphate (Na 5 P 3 O 10 )
  • compositions e.g., antiperspirants and/or deodorants, comprising the aqueous soluble tin phosphate complexes.
  • antiperspirants and/or deodorants comprising the aqueous soluble tin phosphate complexes that form a precipitate when contacted with sweat.
  • compositions e.g., antiperspirants and/or deodorants, comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ), e.g., sodium tripolyphosphate (Na 5 P 3 O 10 ), e.g., wherein the tin (II) fluoride or tin (II) chloride and tripolyphosphate salt form an aqueous soluble tin phosphate complex.
  • a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ), e.g., sodium tripo
  • compositions e.g., antiperspirants
  • aqueous soluble tin phosphate complexes comprising combining tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., sodium tripolyphosphate, in aqueous solution, e.g., at a molar ratio of 1P: 1Sn to less than 15P: 1Sn, e.g., greater than 1P : 1Sn to less than 15P : 1Sn, e.g., 2P : 1Sn to less than 15P : 1Sn, e.g., 2P : 1Sn to 10P : 1Sn, e.g., 2P : 1Sn to 5P : 1Sn; optionally isolating the complexes thus formed as a solid.
  • a tripolyphosphate salt e.g., an alkali tripolyphosphate salt,
  • compositions e.g., antiperspirants
  • methods of making the external personal care compositions comprising admixing the aqueous soluble tin phosphate complexes with a personal care carrier.
  • ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
  • aqueous soluble tin phosphate complex (Complex 1), e.g.,
  • Method 1 to occlude pores and/or reduce sweat, in a person in need thereof comprising applying an effective amount of any of Complex 1 et seq. to the skin of the person.
  • Method 2 of making an aqueous soluble tin phosphate complex, e.g., any of Complex 1 et seq., comprising combining tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate or sodium tripolyphosphate, e.g.,
  • aqueous soluble tin phosphate complex made by any of Method 2 et seq.
  • composition 1 an external personal care composition
  • Composition 1 e.g., an antiperspirant, deodorant, body wash, shower gel, soap (e.g., bar soap, hand soap), shampoo, hair conditioner, or cosmetic
  • tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ) (STPP), e.g., any of Complex 1 et seq., e.g.,
  • Method 3 to occlude pores and/or reduce sweat, in a person in need thereof comprising applying an effective amount of an external personal care composition comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., potassium tripolyphosphate (K 5 P 3 O 10 ) or sodium tripolyphosphate (Na 5 P 3 O 10 ) (STPP), e.g., any of Composition 1 et seq., to the skin of the person, e.g.,
  • Method 4 of making an external personal care composition comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., an alkali tripolyphosphate salt, e.g., sodium tripolyphosphate, e.g., any of Composition 1 et seq., comprising mixing tin (II) fluoride or tin (II) chloride and the tripolyphosphate salt with a personal care carrier, e.g.,
  • Tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., sodium tripolyphosphate
  • a pre-formed aqueous soluble tin phosphate complex e.g., any of Complex 1 et seq., which may be prepared in bulk, and then incorporated into the external personal care compositions disclosed herein, e.g., any of Composition 1 et seq.
  • tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., sodium tripolyphosphate
  • a tripolyphosphate salt e.g., an alkali tripolyphosphate salt, e.g., sodium tripolyphosphate
  • the carrier can be any carrier that is used for antiperspirants and/or deodorants.
  • the carrier can be in the form of a stick, a gel, a roll-on, or an aerosol (e.g. spray).
  • the carrier may include oils and/or silicones and gelling agents.
  • Optional ingredients that may be included in an antiperspirant and/or deodorant disclosed herein, e.g., any of Composition 1 et seq., include solvents; water-soluble alcohols such as C 2-8 alcohols; glycols; glycerides including mono-, di- and triglycerides; medium to long chain organic acids, alcohols, and esters; surfactants including emulsifying and dispersing agents; amino acids; structurants including thickeners and gelling agents, for example polymers, silicates, and silicon dioxide; emollients; fragrances; and colorants including dyes and pigments.
  • solvents water-soluble alcohols such as C 2-8 alcohols
  • glycols such as C 2-8 alcohols
  • glycerides including mono-, di- and triglycerides
  • surfactants including emulsifying and dispersing agents
  • amino acids including thickeners and gelling agents, for example polymers
  • the complexes disclosed herein can be formulated into topical antiperspirants and/or deodorants suitable for application to skin, illustratively a stick, a gel, a cream, a roll-on, a soft solid, a powder, a liquid, an emulsion, a suspension, a dispersion, or a spray.
  • the compositions disclosed herein, e.g., any of Composition 1 et seq. can comprise a single phase or can be a multi-phase system, for example a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion.
  • compositions disclosed herein can be liquid, semi-solid, or solid.
  • Antiperspirants and/or deodorants may be provided in any suitable container such as an aerosol can, tube, or container with a porous cap, roll-on container, bottle, container with an open end, etc.
  • complexes disclosed herein e.g., any of Complex 1 et seq.
  • body washes and soaps e.g., hand soaps
  • the complexes and compositions disclosed herein may be destructive to or inhibit the growth of bacteria.
  • the complexes disclosed herein e.g., any of Complex 1 et seq.
  • the formation of precipitate of the complexes and compositions disclosed herein e.g., any of Complex 1 et seq., e.g., any of Composition 1 et seq., may provide a residual antibacterial effect.
  • the complexes and compositions disclosed herein may be used in a method to reduce sweating by applying the complex and/or composition to skin.
  • the application is to axilla.
  • a method for controlling perspiration comprising applying to skin an antiperspirant effective amount of a complex or a composition disclosed herein, e.g., any of Complex 1 et seq., e.g., any of Composition 1 et seq.
  • a complex disclosed herein may be described by reference to a spectrum as "substantially” shown or depicted in a figure or by one or more data points. It will be appreciated that a Fourier transform infrared, Raman, or NMR spectrum of a given sample may vary depending on factors known to those of skill in the art, e.g., instrument used, etc. Therefore, the Fourier transform infrared, Raman, and NMR spectrum peaks set forth herein will have an acceptable level of deviation.
  • the peaks may have an acceptable deviation of, e.g., ⁇ 20 cm -1 or ⁇ 16 cm -1 or ⁇ 4 cm -1 or ⁇ 2 cm -1 or ⁇ 1 cm -1 or ⁇ 0.5 cm -1 .
  • the peaks may have an acceptable deviation of, e.g., ⁇ 1-2 cm -1 , e.g., ⁇ 1 cm -1 , e.g., ⁇ 2 cm -1 .
  • the peaks may have an acceptable deviation of, e.g., ⁇ 1 ppm.
  • external means suitable for application to the skin, including the scalp, and nails.
  • aqueous solution means a solution in which the solvent is water.
  • aqueous soluble tin phosphate complex includes a complex in which 1 gram of the complex is soluble in 1 or 10 to 100 ml water, e.g., 1 or 10 to 90 ml water, e.g., 1 or 10 to 80 ml water, e.g., 1 or 10 to 70 ml water, e.g., 1 or 10 to 60 ml water, e.g., 1 or 10 to 50 ml water, e.g., 1 or 10 to 40 ml water, e.g., 1 or 10 to 30 ml water, e.g., 1 or 10 to 20 ml water, e.g., 1-10 ml water, e.g., less than 1 ml water.
  • STPP sodium tripolyphosphate
  • SnF 2 stannous fluoride
  • the solutions with a P:Sn molar ratio spanning from 1 to 15 containing 2% SnF2 are aged overnight at room temperature. After overnight aging, only the solutions with a P:Sn molar ratio spanning from 2 to 10 remain clear.
  • Bovine serum albumin simulates sweat proteins and may reveal the benefit of the complex in antiperspirants, as the formation of precipitate may block sweat ducts.
  • the solutions with a P:Sn molar ratio of 2 and 5 containing 1% bovine serum albumin (BSA) are aged at 37°C and at room temperature overnight.
  • a 1% BSA control after aging overnight at room temperature shows no precipitate.
  • a 1% BSA control after aging overnight at 37°C shows no precipitate.
  • compositions comprising elevated concentrations of a complex comprising tin (II) fluoride and a polyphosphate, having a P:Sn molar ratio of 2, are evaluated.
  • Table 3 P:Sn Molar Ratio Amount (g) Percent in Solution 2 0.2 SnF 2 9% Solution remains clear 1.6 STPP 15% STPP solution 14% - 78% 2 0.2 SnF 2 10% Solution is clear upon preparation but becomes turbid overnight 0.2 STPP 16% 1.2 H 2 O 74% 2 0.2 SnF 2 11% Does not form a clear solution 0.2 STPP 18% 1 H 2 O 71%
  • a clear solution comprising 2% stannous fluoride (SnF 2 ) and sodium tripolyphosphate (STPP) with a P:Sn molar ratio of 5 is lyophilized using a Labconco FreeZone 2.5 Freeze Dryer.
  • FTIR-ATR analysis is conducted on freeze dried powder on an extended range Spectrum One Perkin Elmer system featuring a Cs1 beam splitter, DTGS detector, and single-bounce diamond KRS-5 ATR crystal. Sample is placed directly on the ATR diamond. See Figure 1 . Peaks observed for the Sn-STPP complex are listed in Table 4 (broad peaks from water/ethanol at about 1640 and 3200 cm -1 are omitted from peak table).
  • Ethanol is added dropwise to a clear solution comprising 2% stannous fluoride (SnF 2 ) and sodium tripolyphosphate (STPP) with a P:Sn molar ratio of 5 until precipitate forms.
  • Solid is filtered and air dried.
  • FTIR-ATR analysis is conducted on solid on an extended range Spectrum One Perkin Elmer system featuring a CsI beam splitter, DTGS detector, and single-bounce diamond KRS-5 ATR crystal. Sample is placed directly on the ATR diamond. See Figure 2 .
  • An FTIR-ATR for solid SnF 2 is in Figure 6 .
  • FTIR-ATR analysis may be conducted on about 10-100 mg of solid.
  • the solutions are aged overnight at room temperature. After 24 hours, the solutions containing a P/Sn molar ratio of 3 and 5 remain clear. The solutions with P/Sn molar ratios of 1, 2, and 15 are turbid and the solution with a P/Sn molar ratio of 10 appears slightly cloudy.
  • Solutions of 2% SnF 2 and STPP in water with P/Sn molar ratios of 2, 5, and 10 are prepared. 5 weight % D 2 O is added to the solutions.
  • 31 P and 119 Sn NMR are acquired on a Bruker AVANCE 500 spectrometer working at 202.4 MHz for 31 P NMR and 163.5 MHz for 119 Sn NMR at room temperature.
  • 31 P NMR are externally referenced to 85% H 3 PO 4 set to 0 ppm.
  • 119 Sn NMR are externally referenced to saturated SnF 2 in D 2 O at -796 ppm prepared right before measurement.
  • Figures 4a, 4b, and 4c depict 31 P NMR spectra of solutions with P:Sn molar ratios of 10 ( Figure 4a ), 5 ( Figure 4b ), and 2 ( Figure 4c ).
  • Figures 5a, 5b, and 5c depict 119 Sn NMR spectra of solutions with P:Sn molar ratios of 10 ( Figure 5a ), 5 ( Figure 5b ), and 2 ( Figure 5c ).
  • 31 P NMR peaks are listed in Table 7 and 119 Sn NMR peaks are listed in Table 8.
  • a 31 P NMR spectrum of a solution of STPP in water with 5 weight % D 2 O added and externally referenced to 85% H 3 PO 4 set to 0 ppm is in Figure 7 .
  • a roll-on antiperspirant comprising the aqueous soluble tin phosphate complex as disclosed herein can be formulated as described in Table 9 (below).
  • Table 9 Material Weight Percent Aqueous soluble tin phosphate complex 5-30% Surfactant(s) 1-30%, e.g., 5% Emollient(s) 1-10%, e.g., 2% Silicone(s) 1-10%, e.g., 2% Fragrance(s) 0.5-5%, e.g., 1% Water Q.S.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16826653.4A 2015-12-30 2016-12-28 Personal care compositions Active EP3380065B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273306P 2015-12-30 2015-12-30
PCT/US2016/069035 WO2017117301A1 (en) 2015-12-30 2016-12-28 Personal care compositions

Publications (2)

Publication Number Publication Date
EP3380065A1 EP3380065A1 (en) 2018-10-03
EP3380065B1 true EP3380065B1 (en) 2020-05-13

Family

ID=57799928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16826653.4A Active EP3380065B1 (en) 2015-12-30 2016-12-28 Personal care compositions

Country Status (7)

Country Link
US (1) US10123952B2 (ru)
EP (1) EP3380065B1 (ru)
CN (1) CN108472209B (ru)
BR (1) BR112018012947B1 (ru)
MX (1) MX370240B (ru)
RU (1) RU2731093C2 (ru)
WO (1) WO2017117301A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3941594B1 (en) * 2019-03-18 2022-10-12 Unilever IP Holdings B.V. An antiperspirant composition comprising reactive salts
EP3941593B1 (en) * 2019-03-18 2022-10-12 Unilever IP Holdings B.V. An antiperspirant composition comprising reactive salts

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2145583A (en) 1934-12-06 1939-01-31 Victor H Roehrich Antisudorific deodorizing shaving cream
US2236387A (en) 1938-05-03 1941-03-25 Wallace Jr Perspiration inhibiting composition
BE539808A (ru) 1953-07-08
US3028216A (en) 1956-05-25 1962-04-03 Monsanto Chemicals Methods of preparing stannous pyrophosphate
US3934004A (en) * 1973-03-09 1976-01-20 Orren Leonard J Stain resistant anti-perspirant composition
US4071613A (en) 1976-02-26 1978-01-31 Abbott Laboratories Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation
US4198394A (en) 1978-07-25 1980-04-15 Faunce Frank R Sodium dihydrogen phosphate enhanced dentifrice composition
US4292306A (en) 1978-12-28 1981-09-29 Faunce Frank R Dentifrice with topical and systemic phosphate fluoride system
US4340583A (en) 1979-05-23 1982-07-20 J. M. Huber Corporation High fluoride compatibility dentifrice abrasives and compositions
US4330680A (en) 1980-10-28 1982-05-18 Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Integrated series-connected solar cell
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US5004597A (en) 1987-09-14 1991-04-02 The Procter & Gamble Company Oral compositions comprising stannous flouride and stannous gluconate
US5000944A (en) 1989-06-09 1991-03-19 Colgate-Palmolive Company Zinc-containing oral products with reduced astringency
US5188820A (en) 1989-10-05 1993-02-23 Chesebrough-Pond's Usa Co., Dividion Of Conopco, Inc. Method of inhibiting plaque on teeth by applying an oral composition
US5017363A (en) 1989-11-15 1991-05-21 Gillette Canada, Inc. Stabilized stannous fluoride toothpaste
US4961924A (en) 1989-11-15 1990-10-09 Gillette Canada Inc. Stabilized stannous fluoride toothpaste
GB9110721D0 (en) 1991-05-17 1991-07-10 Unilever Plc Dentifrice compositions
US5281410A (en) 1991-10-23 1994-01-25 The Proctor & Gamble Company Methods of reducing plaque and gingivitis with reduced staining
US5213790A (en) 1991-10-23 1993-05-25 The Procter & Gamble Co. Methods of reducing plaque and gingivitis with reduced staining
US5145666A (en) 1991-10-23 1992-09-08 The Proctor & Gamble Co. Methods of reducing plaque and gingivitis with reduced staining
JP3165247B2 (ja) 1992-06-19 2001-05-14 シスメックス株式会社 粒子分析方法及び装置
US5281411A (en) 1992-07-31 1994-01-25 The Procter & Gamble Company Oral compositions
US5338537A (en) 1993-10-05 1994-08-16 The Procter & Gamble Company Oral compositions
US5599527A (en) 1994-11-14 1997-02-04 Colgate-Palmolive Company Dentifrice compositions having improved anticalculus properties
US5578293A (en) 1994-12-06 1996-11-26 Colgate Palmolive Company Oral compositions containing stabilized stannous compounds having antiplaque and antitartar efficacy
US5487906A (en) * 1994-12-15 1996-01-30 Colgate-Palmolive Company Method of forming stable aqueous solutions of stannous compounds
US5716600A (en) 1995-11-14 1998-02-10 Professional Dental Technologies, Inc. Stable stannous fluoride toothpaste compositions
US6187295B1 (en) 1996-11-21 2001-02-13 The Procter & Gamble Company Methods of reducing the astringency of stannous in dentifrice compositions
US6190644B1 (en) 1996-11-21 2001-02-20 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and monofluorophosphate
US6350436B1 (en) 1996-11-21 2002-02-26 The Procter & Gamble Company Method of reducing staining of stannous in dentifrice compositions
US5939052A (en) 1996-11-21 1999-08-17 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and fluoride
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
US5939051A (en) 1998-02-27 1999-08-17 Colgate-Palmolive Company Dental abrasive
US6464963B1 (en) 1998-04-23 2002-10-15 Colgate Palmolive Company Desensitizing dentifrice containing potassium and tin salts
US6605289B1 (en) 1998-06-09 2003-08-12 Embro Research Company, Llc. Method and composition for the treatment of epidermal irritations and infections
US7387774B2 (en) 1999-11-12 2008-06-17 The Procter & Gamble Co. Method of enhancing fluoridation and mineralization of teeth
US9139731B2 (en) 1999-11-12 2015-09-22 The Procter & Gamble Company Compositions and methods for improving overall tooth health and appearance
US20070025928A1 (en) 1999-11-12 2007-02-01 The Procter & Gamble Company Stannous oral care compositions
EP1227788B1 (en) 1999-11-12 2010-08-11 The Procter & Gamble Company Oral compositions containing stannous ions
US6685920B2 (en) 1999-11-12 2004-02-03 The Procter & Gamble Company Method of protecting teeth against erosion
AU2001271545A1 (en) 2000-06-30 2002-01-14 The Procter And Gamble Company Promoting whole body health
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
CN100408016C (zh) 2001-06-25 2008-08-06 宝洁公司 口腔组合物
MXPA04005066A (es) 2001-11-28 2004-08-19 Procter & Gamble Composiciones dentifricas que contienen una fase estable con bajo contenido de agua que comprende polifosfato e ingredientes activos ionicos.
US6652841B1 (en) 2002-08-28 2003-11-25 Colgate Palmolive Company Antiplaque enzyme containing dual component composition
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US9072658B2 (en) 2003-02-05 2015-07-07 Fmc Corporation Toothpaste compositions with reduced abrasivity
JP4770407B2 (ja) * 2005-09-20 2011-09-14 株式会社アドヴィックス 負圧式倍力装置
CN101360474A (zh) * 2005-11-23 2009-02-04 高露洁-棕榄公司 包含亚锡盐和三聚磷酸钠的口腔护理组合物及方法
CA2634758A1 (en) * 2005-12-20 2007-07-05 The Procter & Gamble Company Oral care compositions comprising zinc and phytate
AU2006330508B2 (en) 2005-12-21 2010-02-25 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate and/or tocopherol agents
US8628755B2 (en) 2007-01-30 2014-01-14 Colgate-Palmolive Company Dentifrice containing zinc ions and polyphosphate ions
RU2448680C2 (ru) 2007-11-09 2012-04-27 Дзе Проктер Энд Гэмбл Компани Композиции для полости рта, содержащие олово
ES2560202T3 (es) 2008-11-25 2016-02-17 The Procter & Gamble Company Composiciones para el cuidado bucal con sílice fundida
CN102596154B (zh) 2009-10-29 2014-12-24 高露洁-棕榄公司 包含氟化亚锡加柠檬酸锌和低水平水的洁齿剂
US20120276177A1 (en) * 2009-12-23 2012-11-01 Colgate-Palmolive Company Visually patterned and oriented compositions
AU2010363319B2 (en) 2010-11-04 2015-02-19 Colgate-Palmolive Company Dentifrice composition with reduced astringency
RU2560687C2 (ru) 2010-12-21 2015-08-20 Колгейт-Палмолив Компани Композиции солей металла
AU2011369408B2 (en) 2011-06-02 2015-08-20 Colgate-Palmolive Company Low water metal ion dentifrice
CA2840500A1 (en) 2011-07-12 2013-01-17 The Proctor & Gamble Company Oral care compositions comprising phytic acid
US8956593B2 (en) 2011-09-01 2015-02-17 The Procter & Gamble Co. Oral care compositions with improved rheology
BR112015024772A2 (pt) 2013-04-10 2017-07-18 Procter & Gamble composições para tratamento bucal contendo partículas de poli-organossilsesquioxano
KR102137049B1 (ko) * 2013-07-25 2020-07-24 주식회사 에이텍에이피 조명 장치, 조명 장치 시스템 및 조명장치의 등록 방법
AU2013399515B2 (en) * 2013-09-02 2017-08-10 Block Drug Company Inc Novel dentifrice composition
BR112016028403B1 (pt) 2014-06-20 2020-12-15 Colgate-Palmolive Company Composição para cuidado oral contendo fontes de íons de zinco, estanho e fluoreto e uso de tais fontes para a preparação de uma composição para cuidado oral
CN106413815B (zh) 2014-06-20 2019-06-14 高露洁-棕榄公司 含有金属离子的口腔组合物
CA2971409C (en) 2014-12-26 2022-01-11 Colgate-Palmolive Company Low water dentifrice compositions
WO2016178652A1 (en) * 2015-05-01 2016-11-10 Colgate-Palmolive Company Low water dentifrice compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
MX370240B (es) 2019-12-06
BR112018012947B1 (pt) 2021-08-31
MX2018007864A (es) 2018-08-27
CA3009827A1 (en) 2017-07-06
EP3380065A1 (en) 2018-10-03
CN108472209A (zh) 2018-08-31
BR112018012947A2 (pt) 2018-12-11
RU2018123778A (ru) 2019-12-30
US10123952B2 (en) 2018-11-13
RU2018123778A3 (ru) 2020-03-24
CN108472209B (zh) 2021-06-25
RU2731093C2 (ru) 2020-08-28
US20170360664A1 (en) 2017-12-21
WO2017117301A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US11344486B2 (en) Zinc phosphate complex
EP3380065B1 (en) Personal care compositions
EP3223913B1 (en) Zinc phosphate complex
CA2972236C (en) Personal care compositions with zinc phosphate active
US20170340534A1 (en) Zinc Phosphate Complex
CA2971579C (en) Zinc phosphate complex for oral care
EP3380064B1 (en) Personal care compositions
US11020330B2 (en) Personal care composition with Zinc phosphate active
CA3009827C (en) Personal care compositions comprising tripolyphosphate and tin fluoride or tin chloride
US20230218496A1 (en) Ionic liquid as an antiperspirant
US9861562B2 (en) Occlusive personal care composition
WO2017105438A1 (en) Occlusive personal care composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200102

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016036516

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1269308

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200615

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200913

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200914

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200813

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200814

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200813

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1269308

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016036516

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602016036516

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241227

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20241226

Year of fee payment: 9